LUNG Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

21.73M

-8.57%

-0.385

+16.67%

22.65M

+0.48%

-0.340

-5.56%

23.06M

-3.35%

-0.332

-12.63%

Estimates Revision

The market is revising Downward the revenue expectations for Pulmonx Corporation (LUNG) for FY2025, with the revenue forecasts being adjusted by -0.72% over the past three months. During the same period, the stock price has changed by 29.11%.

Revenue Estimates for FY2025

Revise Downward

-0.72%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-5.49%

In Past 3 Month

Stock Price

Go Up

+29.11%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast LUNG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LUNG is 4.10 USD with a low forecast of 2.50 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

2 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

2.50

Averages

4.10

High

6.00

Current: 0.000

Low

2.50

Averages

4.10

High

6.00

Lake Street

Buy

downgrade

$8 -> $4

2025-10-28

Reason

Lake Street

Price Target

$8 -> $4

2025-10-28

downgrade

Buy

Reason

Lake Street lowered the firm's price target on Pulmonx to $4 from $8 and keeps a Buy rating on the shares. While the return of former CEO Glen French and CFO Derrick Sung was "certainly surprising," the firm believes the Street will view the return of prior leadership positively, the analyst tells investors. The firm, which continues to think shares are attractive given the "vast clinical verification/proof of concept of Zephyr valves," and the market opportunity and new product pipeline, notes that its lowered price target still "supports an approximate double from after-hours prices."

Citi

Neutral

downgrade

2025-05-22

Reason

Citi

Price Target

2025-05-22

downgrade

Neutral

Reason

Citi lowered the firm's price target on Pulmonx to $4.15 from $6.50 and keeps a Neutral rating on the shares. The firm updated models in medical technology following the Q1 reports. The good news is that underlying sector fundamentals appear intact, including volumes, pricing, and capex, the analyst tells investors in a research note.

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$17

2025-03-11

Reason

D. Boral Capital

Jason Kolbert

Price Target

$17

2025-03-11

Maintains

Strong Buy

Reason

D. Boral Capital initiated coverage of Pulmonx with a Buy rating and $17 price target. The firm says Pulmonx is a commercial-stage medical technology company developing minimally invasive treatments for severe emphysema, a form of chronic obstructive pulmonary disease. With increasing physician adoption of the company's Zephyr Endobronchial Valve, strong reimbursement tailwinds, and international expansion opportunities, Pulmonx is well positioned for "significant growth," the analyst tells investors in a research note.

D. Boral Capital

Jason Kolbert

Strong Buy

Initiates

$17

2025-03-10

Reason

D. Boral Capital

Jason Kolbert

Price Target

$17

2025-03-10

Initiates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Pulmonx Corp (LUNG.O) is -1.65, compared to its 5-year average forward P/E of -11.44. For a more detailed relative valuation and DCF analysis to assess Pulmonx Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-11.44

Current PE

-1.65

Overvalued PE

-0.33

Undervalued PE

-22.55

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-11.51

Current EV/EBITDA

-1.47

Overvalued EV/EBITDA

1.87

Undervalued EV/EBITDA

-24.88

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

10.04

Current PS

1.04

Overvalued PS

20.43

Undervalued PS

-0.35

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 1169.71% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

LUNG News & Events

Events Timeline

No data

News

3.5

2025-12-09Globenewswire

Lungpacer Launches AeroPace System, Enabling Rapid Weaning for ICU Patients

5.0

2025-12-03Globenewswire

Pulmonx Grants 1.625 Million Equity Awards to Attract Executives

5.0

2025-12-03Newsfilter

Pulmonx Grants 1.625 Million Equity Awards to Attract Executives

People Also Watch

Frequently Asked Questions

What is Pulmonx Corp (LUNG) stock price today?

The current price of LUNG is 2.04 USD — it has decreased -2.86 % in the last trading day.

What is Pulmonx Corp (LUNG)'s business?

Pulmonx Corporation is a commercial-stage medical technology company. The Company provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.

What is the price predicton of LUNG Stock?

What is Pulmonx Corp (LUNG)'s revenue for the last quarter?

Pulmonx Corp revenue for the last quarter amounts to 21.50M USD, increased 5.47 % YoY.

What is Pulmonx Corp (LUNG)'s earnings per share (EPS) for the last quarter?

Pulmonx Corp. EPS for the last quarter amounts to -0.34 USD, decreased -5.56 % YoY.

What changes have occurred in the market's expectations for Pulmonx Corp (LUNG)'s fundamentals?

How many employees does Pulmonx Corp (LUNG). have?

Pulmonx Corp (LUNG) has 291 emplpoyees as of January 10 2026.

What is Pulmonx Corp (LUNG) market cap?

Today LUNG has the market capitalization of 84.14M USD.